Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Hatzis

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Cell Reports|November 8, 2018
Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic HeterogeneityWeiwei Shi, Charlotte K Y Ng, Raymond S Lim, et al.
Molecular Cancer Therapeutics|March 29, 2018
Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy TrialVasiliki Pelekanou, William E Barlow, Zeina A Nahleh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2010
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancersGiampaolo Bianchini, Yuan Qi, Ricardo H Alvarez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistryTakayuki Iwamoto, Daniel Booser, Vicente Valero, et al.
Genome Medicine|April 27, 2021
Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancersXiaotong Li, Sushant Kumar, Arif Harmanci, et al.
NPJ Precision Oncology|February 16, 2023
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancersMaysa M Abu-Khalaf, K Alex Hodge, Christos Hatzis, et al.
Cancer Research|March 5, 2022
Comprehensive Analysis of Metabolic Isozyme Targets in CancerMichal Marczyk, Vignesh Gunasekharan, David Casadevall, et al.
Breast Cancer Research and Treatment|February 4, 2018
Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancerJulia Foldi, Sarah Mougalian, Andrea Silber, et al.
Breast Cancer Research : BCR|January 13, 2010
Effect of training-sample size and classification difficulty on the accuracy of genomic predictorsVlad Popovici, Weijie Chen, Brandon G Gallas, et al.
Cancer|February 5, 2015
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumorsMaysa M Abu-Khalaf, Megan A Baumgart, Scott N Gettinger, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Cell Reports|November 8, 2018
Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic HeterogeneityWeiwei Shi, Charlotte K Y Ng, Raymond S Lim, et al.
Molecular Cancer Therapeutics|March 29, 2018
Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy TrialVasiliki Pelekanou, William E Barlow, Zeina A Nahleh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2010
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancersGiampaolo Bianchini, Yuan Qi, Ricardo H Alvarez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistryTakayuki Iwamoto, Daniel Booser, Vicente Valero, et al.
Genome Medicine|April 27, 2021
Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancersXiaotong Li, Sushant Kumar, Arif Harmanci, et al.
NPJ Precision Oncology|February 16, 2023
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancersMaysa M Abu-Khalaf, K Alex Hodge, Christos Hatzis, et al.
Cancer Research|March 5, 2022
Comprehensive Analysis of Metabolic Isozyme Targets in CancerMichal Marczyk, Vignesh Gunasekharan, David Casadevall, et al.
Breast Cancer Research and Treatment|February 4, 2018
Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancerJulia Foldi, Sarah Mougalian, Andrea Silber, et al.
Breast Cancer Research : BCR|January 13, 2010
Effect of training-sample size and classification difficulty on the accuracy of genomic predictorsVlad Popovici, Weijie Chen, Brandon G Gallas, et al.
Cancer|February 5, 2015
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumorsMaysa M Abu-Khalaf, Megan A Baumgart, Scott N Gettinger, et al.
Pageof 10